Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYH9061
- Development stage
- Phase 2
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
SYH9061 is an inhaled dry powder formulation of nintedanib esilate, a small molecule tyrosine kinase inhibitor, being developed by CSPC Pharmaceutical Group and its subsidiary Beijing Kangchuanglian Biopharmaceutical Technology Research for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib acts as a triple angiokinase inhibitor, targeting vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-3), and platelet-derived growth factor receptors (PDGFR-alpha/beta). By delivering nintedanib directly to the lungs via inhalation, SYH9061 aims to achieve high local concentrations in the lung tissue while minimizing systemic exposure and associated side effects (such as gastrointestinal toxicity) compared to oral nintedanib. It is currently in Phase II clinical development in China.
- Other names
- nintedanib esilate dry powder for inhalationnintedanib esilate inhalation powder乙磺酸尼达尼布吸入粉雾剂
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on SYH9061.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYH9061.